NCNA.US NuCana PLC

Healthcare Biotechnology USA Stocks
0.9326 USD
Close of Nov 15, 2026
0.8631 4.55
Market cap
USD 3.88M
P/E
-
P/B
0.14x
ROE
-57.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NCNA.US undervalued?

Graham number

The Graham number of NuCana PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NuCana PLC fundamental analysis

No fundamental analysis for NuCana PLC yet.

NuCana PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NuCana PLC

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derive…

Full company profile